Abstract

Necroptosis is a recently discovered form of programmed cell death (PCD) having necrotic-like morphology. However, its presence and potential impact with respect to head and neck squamous cell carcinoma (HNSCC) are still unknown. The aim of this study was to reveal the necroptosis status and its clinicopathological relevance in HNSCC and to establish an in vitro model. We first analyzed the level of p-MLKL, MLKL, and tumor necrosis in HNSCC patient tissues as well as their correlation with clinicopathological features. Results showed that approximately half of the tumor necrosis can be attributed to necroptosis, and the extent of necroptosis is an independent prognostic marker for patient’s overall survival and progression-free survival. Then we established and thoroughly verified an in vitro model of necroptosis in two HNSCC cell lines using combined treatment of TNF-α, Smac mimetic and zVAD-fmk (TSZ). At last, we adopted this model and demonstrated that necroptosis can promote migration and invasion of HNSCC cells by releasing damage-associated molecular patterns. In conclusion, our study unveiled the necroptotic status in HNSCC for the first time and provided a novel in vitro model of necroptosis in two HNSCC cell lines. In addition, our results indicated that necroptosis may be a potential cancer promoter in HNSCC. This study may serve as the foundation for future researches of necroptosis in HNSCC.

Highlights

  • Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent cancers worldwide

  • We found the p-RIP3 was more widely stained than p-MLKL and not restrained to necrotic clusters

  • These results clearly suggest that approximately half of the “necrotic foci” traditionally observed in head and neck squamous cell carcinoma (HNSCC) tissues can be owing to necroptosis

Read more

Summary

Introduction

Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent cancers worldwide. It was responsible for ~800,000 newly diagnosed cases and. Even though there have been significant advances in the multimodal treatment of HNSCC, the long-term survival rates are still between 40 and 50%. Further improvements in therapeutic strategies are needed especially for the patients with advanced-stage cancers[2]. Yat-sen University, Guangzhou, Guangdong, People’s Republic of China. These authors contributed : Jingyuan Li, Sihui Huang, Lijuan Zeng. Sun for the treatment failure in HNSCC. Previous studies have demonstrated that tumor cell apoptotic resistance is one of the principal mechanisms behind chemoresistance[3]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call